Digest Network Come funziona
Network
/
Società
Mo
Non verificato

Monument Therapeutics

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaOrganizzazione AziendaleSanità

5 comunicati stampa

Guarda tutti i comunicati
17/04/2025
Farmaceutica
Information Technology
Telecomunicazioni
Sanità
Economia
Management
Organizzazione Aziendale
Biologia
Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
Fonte
Monument Therapeutics
Emittente
PR News Wire
1.00
0
Press Release cover image
26/11/2024
Farmaceutica
Sanità
Biologia
Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Fonte
Monument Therapeutics
Emittente
PR News Wire
1.00
0
Press Release cover image
19/11/2024
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Biologia
Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Fonte
Monument Therapeutics
Emittente
PR News Wire
1.00
0
Press Release cover image
15/10/2024
Farmaceutica
Information Technology
Telecomunicazioni
Banca
Sanità
Economia
Management
Organizzazione Aziendale
Biologia
Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth
Fonte
Monument Therapeutics
Emittente
PR News Wire
1.00
0
Press Release cover image
17/09/2024
Farmaceutica
Sanità
Biologia
Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980
Fonte
Monument Therapeutics
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0